The pivot to M&A diligence

Here is the thing about product-market fit that nobody tells you. You can have users who love the product, a published case study, and a Nobel laureate's lab on your customer list, and *still* not have a market. Gladstone was getting real value from Colabra. The product worked. The problem was that isolated customer wins were not the same thing as a durable, urgent, budgeted market.

R&D collaboration software was not a large enough budget priority for the buyers we could reach. Smaller biotech companies could not justify the spend. Larger ones had budget, but the cycle to close them was 12 months or more, the integration burden was enormous, and their spending skewed toward clinical development rather than research operations. The unit economics of selling R&D software into that market were bad.

The move into buy-side diligence came after we experienced an acquisition data room process ourselves. Philip and I looked at the pain and realized it was more urgent, better budgeted, and structurally similar to the problem we had already been working on. Large volumes of unstructured documents. Fragmented workflows. Permissions management. The need for reliable categorization and traceable outputs. It was the same problem in a different costume.

We looked at other directions. Healthcare RCM. Sell-side VDR ideas. Buy-side diligence was the most natural fit, required the least one-way rebuild, and had the clearest buyer with an urgent problem. The pivot was less a reset than a tightening. We kept the core document-analysis and workflow infrastructure, changed the buyer and use case, and repositioned the product around what customers actually wanted: diligence AI software, not another place to store files.